End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.91 CNY | +1.60% | +2.53% | -33.33% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 68% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With a 2024 P/E ratio at 28.15 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-33.33% | 763M | - | ||
+11.12% | 39.61B | B | ||
+0.47% | 18.28B | B- | ||
-13.24% | 2.39B | D+ | ||
+4.15% | 1.48B | C+ | ||
+23.58% | 1.19B | - | ||
-35.29% | 744M | B- | ||
-10.47% | 662M | - | ||
+22.22% | 506M | - | - | |
+28.47% | 477M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301101 Stock
- Ratings Mingyue Optical Lens Co.,Ltd.